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Abstract
Background: Inhibition of 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) is being pursued as a new therapeutic
approach for the treatment of obesity and metabolic syndrome. Therefore, there is an urgent need to determine the effect
of 11b-HSD1 inhibitor, which suppresses glucocorticoid action, on adipose tissue inflammation. The purpose of the present
study was to examine the effect of BVT.2733, a selective 11b-HSD1 inhibitor, on expression of pro-inflammatory mediators
and macrophage infiltration in adipose tissue in C57BL/6J mice.
Methodology/Principal Findings: C57BL/6J mice were fed with a normal chow diet (NC) or high fat diet (HFD). HFD treated
mice were then administrated with BVT.2733 (HFD+BVT) or vehicle (HFD) for four weeks. Mice receiving BVT.2733 treatment
exhibited decreased body weight and enhanced glucose tolerance and insulin sensitivity compared to control mice.
BVT.2733 also down-regulated the expression of inflammation-related genes including monocyte chemoattractant protein 1
(MCP-1), tumor necrosis factor alpha (TNF-a) and the number of infiltrated macrophages within the adipose tissue in vivo.
Pharmacological inhibition of 11b-HSD1 and RNA interference against 11b-HSD1 reduced the mRNA levels of MCP-1 and
interleukin-6 (IL-6) in cultured J774A.1 macrophages and 3T3-L1 preadipocyte in vitro.
Conclusions/Significance: These results suggest that BVT.2733 treatment could not only decrease body weight and
improve metabolic homeostasis, but also suppress the inflammation of adipose tissue in diet-induced obese mice. 11b-
HSD1 may be a very promising therapeutic target for obesity and associated disease.
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Introduction
Central obesity, an established risk factor for human health,
plays an important role in the pathogenesis of insulin resistance,
type 2 diabetes, hypertension and cardiovascular disease [1,2].
However, the underlying mechanisms remain largely unknown
[3,4]. Recently, it has been suggested that amplification of
glucocorticoid action within the adipose tissue by the intracellular
enzyme 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) is
involved in the development of central obesity [5,6,7,8,9]. 11b-
HSD1 increases intracellular glucocorticoid levels by converting
inert 11-dehydrocorticosterone (cortisone in humans) to active
corticosterone (cortisol) in adipocyte and macrophages [10,11].
Studies performed in model animals and humans have shown that
11b-HSD1 expression is specifically increased in adipose tissue as
a result of obesity. Furthermore, Masuzaki et al demonstrated that
white adipose tissue (WAT)-specific transgene of 11b-HSD1 could
cause visceral obesity, insulin resistance, diabetes, dyslipidemia,
and hypertension in mice [8]. In contrast, mice with a targeted
disruption of the 11b-HSD1 gene (11b-HSD-1
2/2 mice) exhibited
enhanced glucose tolerance, attenuated gluconeogenic responses,
and improved lipid profile [12,13,14]. These findings suggest that
increased activity of 11b-HSD1 in adipose tissue contributes to
dysfunction of adipose tissue and subsequent metabolic derange-
ment.
Recently, inhibition of 11b-HSD1 has emerged as a new
therapeutic target for the treatment of obesity and metabolic
syndrome [15]. Major pharmaceutical companies are now
engaged in a new wave of drug development for selective 11b-
HSD1 inhibition [16]. These 11b-HSD1 pharmacological inhib-
itors can improve insulin sensitivity and ameliorate metabolic
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[15,17,18].
On the other hand, the profound effects of glucocorticoid on the
immune system preclude its widespread use as a therapeutic agent
for inflammatory diseases [19]. The magnified glucocorticoid
action caused by 11b-HSD1 might serve as an important link at
the interface of inflammation and obesity [20]. Furthermore,
obesity is associated with a chronic low-grade inflammation state,
an important risk factor in cardiovascular disease, which might be
caused by adipocyte hypertrophy together with infiltration of
macrophages into adipose tissue [3]. Therefore, it is imperative
that the effects of 11b-HSD1 inhibitor on the inflammation of
adipose tissue be clarified.
The aim of the present study was to examine the effect of
BVT.2733, a selective inhibitor of 11b-HSD1, on diet induced
obesity with a focus on the expression of pro-inflammatory
mediators and macrophage infiltration in adipose tissue in mice.
Our data affirm the notion that 11b-HSD1 may be a very
promising therapeutic target for obesity and associated disease.
Results
Effect of HFD and BVT.2733 on Adiposity and Metabolic
Parameters
C57BL/6J mice were fed a normal fat diet or HFD for 24
weeks. Mice on HFD showed a significantly higher body weight
gain compared with mice on a NC (data not shown). During the
last four weeks the HFD-fed mice were treated with BVT.2733
(100 mg/kg, orally) (HFD+BVT mice) or vehicle (HFD mice). The
BVT.2733 treatment was not only able to prevent the develop-
ment of obesity, but also caused rapid weight loss (Fig. 1A). Mice
fed on HFD showed glucose intolerance, as evaluated by
intraperitoneal glucose tolerance test (Fig. 1B). However, glucose
tolerance (Fig. 1B) and insulin levels (Fig. 1C) were improved by
BVT.2733 treatment. What’s more, HFD caused marked alter-
ations in the expression of adipokines in adipose tissue including
decreased expression of adiponectin (Fig. 1D) and vaspin (Fig. 1F),
and increased expression of leptin (Fig. 1E). BVT.2733 adminis-
tration normalized the expression profile of adiponkines by up-
regulating the mRNA levels of adiponectin (Fig. 1D) and vaspin
(Fig. 1F) and down-regulating the expression of resistin (Fig. 1G) in
adipose tissue. In line with these changes in adipose tissue serum
levels of adiponectin (Fig. 1H) and leptin (Fig. 1I) were also
improved by BVT.2733 treatment.
Effect of HFD and BVT.2733 Treatment on the
Abundance of Macrophage in Adipose Tissue
To determine the infiltration of macrophages in adipose tissue
after BVT.2733 treatment, immunohistochemistry staining using
a specific macrophage marker F4/80 was performed. As shown
in Fig. 2A, the number of F4/80 positive macrophages was
increased in HFD mice but decreased in HFD+BVT mice. These
results were corroborated by quantitative analysis of the number
of macrophages present in adipose tissue (Fig. 2B). In agreement
with decreased macrophage infiltration, the mRNA expression of
macrophage-specific gene F4/80 (Fig. 2C) and macrophage
inflammatory protein-1a (MIP-1a) (Figure 2E) was down-
regulated in total adipose tissue in HFD+BVT mice compared
to HFD mice. However, there was little change in the expression
of another macrophage marker gene CD68 between HFD and
HFD+BVT mice (Figure 2D). To verify the changes in
macrophage infiltration, cells in the stromal vascular fraction
(SVF) of epididymal fat tissue from both groups of mice were
analyzed by flow cytometry (Figure 3A). The ratio of the F4/80-
positive cells was increased in HFD mice, but decreased in
HFD+BVT mice (Fig. 3B). F4/80-positive cells were further
sorted with anti-CD11c and anti-CD11b antibodies. The data
shown that both the CD11b+ CD11c2 subset of macrophages
(Fig. 3C) and CD11b+ CD11c+ macrophages (Fig. 3D) were
decreased in HFD+BVT mice. Together, these data suggest that
BVT.2733 treatment decreased macrophage infiltration in
adipose tissue in obese mice.
Effect of HFD and BVT.2733 Treatment on the
Inflammation Gene Expression in the Adipose Tissue and
the Level of Circulating Inflammation Markers
Macrophage infiltration of adipose tissue was increased in HFD
mice, and decreased in HFD+BVT mice. Therefore, we investi-
gated the effect of BVT.2733 on the expression and circulating
levels of pro-inflammatory cytokines/chemokines. Total RNA was
isolated from the whole epididymal fat tissues to determine the
expression levels of IL-6, TNF-a and MCP-1 (Fig. 4A, B, C) using
real-time RT-PCR. mRNA levels of MCP-1 and TNF-a, but not
those of IL-6, were increased in adipose tissue of mice fed a HFD
compared to mice fed a NC and BVT.2733 treatment decreased
the expression of TNF-a (P,0.05, n=526) and MCP-1 (P,0.05,
n=526). However, plasma concentrations of IL-6, MCP-1 TNF-
a (Fig. 4D, E) were not decreased in HFD+BVT mice, suggesting
that TNF-a and MCP-1 expressions decreased only locally (within
the adipose tissue).
Effect BVT.2733 on the Inflammation Gene Expression in
PA or LPS-activated J774A.1 Macrophages and 3T3-L1
Preadipocyte in vitro
To further assess the effect of BVT.2733 on the expression of
inflammation genes in macrophages and preadipocyte, we
stimulated murine macrophages (J774A.1) and 3T3-L1 preadipo-
cyte with palmitate (PA) or LPS in vitro. mRNA levels of 11b-
HSD1 and inflammation genes including IL-6, MCP-1 and TNF-
a was increased in macrophages J774A.1 treated with PA or LPS
(Fig. 5A). BVT.2733 attenuated the mRNA levels of MCP-1 and
IL-6 in PA (Fig. 5B) or LPS (Fig. 5C) treated J774A.1
macrophages. The protein levels of MCP-1 and IL-6 in the
medium were also attenuated (Fig. S2A and S2C). However the
mRNA levels of TNF-a were not changed after the treatment of
BVT.2733. Similar results were observed in 3T3-L1 preadipocyte
(Fig. 6A and 6D).
Effect of 11b-HSD1 Knockdown on Proinflammatory
Properties in J774A.1 Macrophages and 3T3-L1
Preadipocytes
To further verify the potential role of 11b-HSD1 in cytokine
expression in activated J774A.1 macrophages and preadipocytes,
11b-HSD1 was depleted using lentiviral-based RNAi. When
J774A.1 macrophages and 3T3-L1 preadipocytes were infected
with 11b-HSD1 shRNA by lentivirus, the expression of 11b-
HSD1 was markedly decreased both at mRNA level (Fig. 5D)
and the protein level (Fig. 5E). Negative control RNAi did not
influence the expression of 11b-HSD1. Consequently, knock-
down of 11b-HSD1 in PA (Fig. 5F) or LPS (Fig. 5G)-treated
J774A.1 macrophages effectively reduced MCP-1 and IL-
6 mRNA levels. Again, the mRNA levels of TNF-a were not
changed after the knocked down of 11b-HSD1 in PA (Fig. 5F)
or LPS (Fig. 5G)-treated J774A.1 macrophages. Similar results
were observed in 3T3-L1 preadipocyte (Fig. 6B and 6E).
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6 in PA or LPS-treated J774A.1 Macrophages and 3T3-L1
Preadipocytes
We next examined whether over-expression of 11b-HSD1 by
lentiviral infection would be sufficient to drive the augmentation of
pro-inflammatory molecules in activated J774A.1 macrophages
and preadipocyte. The over-expression efficiencies were confirmed
by real-time RT-PCR (Fig. 5H) and Western blot (Fig. 5I)
analyses. PA–induced messages of MCP-1, IL-6 and TNF-a were
all augmented by 11b-HSD1 (Fig. 5J). The protein levels of MCP-
1 and IL-6 in the medium were also augmented (Fig. S2B and
S2D). However in LPS-activated macrophage, 11b-HSD1 over-
expression only augmented the expression of MCP-1 (Fig. 5K).
Furthermore, pharmacological inhibition of 11b-HSD1 by
BVT.2733 not only attenuated MCP-1 and IL-6 mRNA levels
(Fig. 5J and 5K) but also protein levels (Fig. S2B and S2D) in these
cells. Similar results were observed in 3T3-L1 preadipocyte
(Fig. 6C and 6F).
Effect of Glucocorticoid Receptor (GR) on
Proinflammatory Properties of 11b-HSD1 in J774A.1
Macrophages
To further investigate the mechanism whereby 11b-HSD1
augments inflammation in activated macrophages and preadipo-
cyte, we treated J774A.1 macrophages with glucocorticoid
antagonist RU486 in the presence of PA. Surprisingly, we found
that RU486 attenuated MCP-1 and IL-6 mRNA levels in
activated J774A.1 macrophages (Fig. 7A). Further more, we found
that lower concentration corticosterone can increased the inflam-
mation in macrophage (Fig. 7B) in steroid hormones free medium.
Normal FBS contains steroid hormones which can act as
substrates for HSD1. Therefore, we repeated our experiments
with different doses of 11-dehydro-corticosterone in J774A.1
macrophages in Charcoal Dextran Stripped Serum media (steroid
hormones free). We found that whereas low concentration 11-
dehydro-corticosterone increased the expression of IL-6, higher
concentration of 11-dehydro-corticosterone suppressed the ex-
pression of IL-6 (Fig. 7C). In addition, J774A.1 macrophages were
transfected with the expression vector for 11b-HSD1 (HSD1) or a
Figure 1. Effect of HDF and BVT.2733 on adiposity and metabolic parameters in C57BL/6J mice. A, Percentage change in body weight.
B–C, Glucose tolerance and plasma insulin level. D–G, Changes in adipose gene mRNA expression. H–I, Serum adiponectin and leptin concentration.
The results are shown as the means 6 SEM. *, P,0.05; **, P,0.01 compared with NC group; #, P,0.05; ##, P,0.01 compared with HFD group.
n=5210 animals per group.
doi:10.1371/journal.pone.0040056.g001
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(100 ng/ml) in the absence (con) or presence of increasing
amounts of 11-dehydro corticosterone (10
211 Mt o1 0
25 M) for
24 h in Charcoal Dextran Stripped Serum media. When lower
concentration 11-dehydro-corticosterone was added in the media,
the expression of IL-6 was increased in HSD1 over-expression
group, however when higher concentration 11-dehydro-cortico-
sterone was added in the media the expression of IL-6 was
suppressed in HSD1 over-expression group (Fig. 7C).
We propose that GCs may exert distinct effects on macrophage
function depending on concentration. 11b-HSD1 may augment
inflammation by increasing the concentration of local glucocor-
ticoid.
Discussion
During the last 10 years, evidence has accumulated that
strongly argues for an etiological role of 11b-HSD1 in obesity
and metabolic syndrome.11b-HSD1 has thus emerged as a major
potential drug target for the treatment of obesity and its
associated medical conditions. BVT.2733 is a new selective
inhibitor of murine 11b-HSD1. In line with previous reports, we
report here that inhibition of 11b-HSD1 by BVT.2733 could not
only prevent the development of obesity, but also cause rapid
weight loss and improve glucose tolerance and insulin levels
[15,17]. What’s more, BVT.2733 treatment for four weeks also
caused a marked increase in the expression of adipokines
including adiponectin and vaspin in adipose tissue in vivo and
we also found that BVT.2733 administration normalized the
expression of vaspin (Fig. S1C) and resistin (Fig. S1D) in PA-
treated adipocyte in vitro. Thus, our findings further confirmed
that BVT.2733 could be regarded as an effective agent that
ameliorates obesity and metabolic syndrome.
Moreover, growing evidence has asserted that obesity is closely
associated with a state of low-grade inflammation in adipose tissue
which is characterized by abnormal cytokine production and
increased macrophages infiltration [21]. This association has been
interpretated as significant in rodents and human studies, and is
causally linked to either obesity itself or closely linked diseases such
as insulin resistance, type 2 diabetes, and cardiovascular disease
[22]. On the other hand, 11b-HSD1 inhibitors might have a
harmful effect on adipose tissue by weakening the anti-inflamma-
tory responses of glucocorticoid. In fact, it has been documented
that 11b-HSD1
2/2mice were more susceptible to endotoxemia
[23] and 11b-HSD1 played an important role in promoting rapid
clearance of apoptotic cells during the resolution of inflammation
[24]. Concomitantly, we observed a dramatic decrease in a series
of inflammation-related genes including MCP-1 and TNF-a in
adipose tissue isolated from HFD+BVT mice compared with HFD
mice. We also observed fewer macrophages accompanied by
down-regulated expression of a panel of macrophages markers in
adipose tissue in HFD+BVT mice. However, macrophages in
adipose tissue do not represent a uniform population of cells but
rather can exhibit a range of activation states. As reported
previously, F4/80, CD11b, and CD11c triple-positive macro-
phages show very high levels of inflammatory markers. These
triple-positive cells account for the majority of the increased
macrophages content in obese adipose tissue [25]. Therefore, we
further analyzed cells in the SVF of epididymal fat tissue from
mice using flow cytometry, and we found decreased ratios of F4/
80-positive and triple-positive cells with the treatment of
BVT.2733. These findings indicate that BVT.2733 may suppress
inflammation in adipose tissue via, at least in part, inhibition of
Figure 2. Effect of HFD and BVT.2733 treatment on the abundance of macrophage in adipose tissue. A–B, Representative
immunohistochemical staining of white adipose tissue using the specific macrophage marker F4/80 and quantification of the of macrophages
present in adipose tissue. C–E, Changes in the expression of macrophage marker genes determined by real time PCR. The results are shown as the
means 6 SEM. *, P, 0.05; **, P, 0.01 compared with NC group; #, P,0.05; ##, P, 0.01 compared with HFD group. n=628 animals per group.
Bar =50 mm.
doi:10.1371/journal.pone.0040056.g002
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vivo.
It is well known that adipose tissue is a composition of an
overwhelming majority of adipocyte, a sizeable majority of
preadipocyte, a smaller number of macrophage and a few other
cell types [26]. It has been suggested that nonadipocytes (e.g. SV
cells) in adipose tissue are the major producers of IL-6 and TNF-a
rather than adipocytes [27]. Macrophage infiltration into obese
adipose tissue contributes to local and systemic inflammation in
subjects with obesity [28]. Recently, it has been suggested that
preadipocytes share certain similarities with macrophages in
phagocytosis and secretion of inflammatory substances [29]. Our
results also indicate that preadipocytes rather than adipocytes play
an essential role in LPS-induced cytokine gene expression as
shown in (Fig. S1A and S1B). For instance, Ishii-Yonemoto found
that TNF-aand IL-1b augmented 11b-HSD1 mRNA expression
and activity in 3T3-L1 preadipocytes [30]. Therefore, we
employed murine macrophages (J774A.1) and 3T3-L1 preadipo-
cyte for in vitro studies. HFD are typically enriched in PA, and
excess nutritional intake may increase plasma and tissue PA
concentrations [31,32]. J774A.1 and 3T3-L1 preadipocyte were
stimulated with PA or LPS. Interestingly, we found that expression
of the inflammation–related genes and 11b-HSD1 were both
substantially increased in PA or LPS activated J774.1 macrophag-
es. Consistent with the results in vivo, we observed BVT.2733 or
11b-HSD1 knockdown decreased expression levels of various
inflammation-related genes, including IL-6 and MCP-1, in
activated macrophages. In contrast, over-expression of 11b-
HSD1 augmented expression of MCP-1 and IL-6 in activated
J774A.1 macrophages and 3T3-L1 preadipocytes. Therefore, our
cell-based and animal results revealed that 11b-HSD1 is an
important regulator at the interface of obesity and inflammation,
and the inhibition of 11b-HSD1 by BVT.2733 could prevent the
development of obesity and reduce the inflammation of adipose
tissue both in vivo and in vitro.
Glucocorticoids have been widely used to treat inflammatory
diseases for almost 60 years due to the potent anti-inflammatory
properties [19], but it has been known to have both permissive and
suppressive effects on gluconeogensis, glycogenolysis and lipolysis
[33]. However, our studies suggest that slight increase of
glucocorticoid by 11b-HSD1 may have a permissive effect on
inflammation. Our data support that over-expression of 11b-
HSD1 augmented MCP-1 and IL-6 in PA or LPS-treated J774A.1
macrophages and 3T3-L1 preadipocytes. Furthermore, we found
glucocorticoid at low concentration can increase the inflammation
in macrophage (Fig.7B). Meanwhile, pharmacological inhibition of
11b-HSD1 and RNA interference against 11b-HSD1 reduced the
mRNA levels of MCP-1 and IL-6. In addition, the expression of
inflammation-related gene augmented by 11b-HSD1 overexpres-
sion was also attenuated by BVT.2733 in macrophages and
preadipocytes. In fact, Lim et al [34] has also reported that
10
210 M of corticosterone enhanced expression of pro-inflamma-
Figure 3. Effect of HFD and BVT.2733 treatment on the number of macrophages in SVF of epididymal fat tissue. Cells in the SVF of
epididymal fat tissue from three groups of mice were analyzed using flow cytometry as described in METHODS section. A, Representative flow
cytometric profiles of cells in the SVF of epdidymal fat tissue derived from NC, HFD, and HFD+BVT mice individually. B, The cell number in F4/80-
positive fraction. C, F4/80-positive/CD11b-positive/CD11c- negetive fraction. D, F4/80-positive/CD11b-positive/CD11c- positive fraction. The results
are shown as the means 6 SEM. *, P,0.05; **, P,0.01 compared with NC group; #, P,0.05; ##, P,0.01 compared with HFD group. n=324 animals
per group.
doi:10.1371/journal.pone.0040056.g003
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(10
27 M–10
26 M) strongly repressed macrophage function. Our
data also supported that low concentration 11-dehydro-cortico-
sterone added in the steroid hormone-free media mimics the
medium supplemented with 10% heat-inactivated FBS, but when
higher concentration of 11-dehydro-corticosterone was added into
the media it acts as an anti-inflammatory hormone. Recently,
Wamil et al [35] demonstrated that HSD1 deficiency also
suppressed inflammation of adipose tissue in obesity. Therefore,
it seems that glucocorticoids may exert both positive and negative
influence on inflammation dependent on their concentrations. It
may open a fresh avenue for molecular and cellular mechanism of
adipose inflammation and dysfunction.
In summary, we demonstrate that treatment of a selective
inhibitor of 11b-HSD1, BVT.2733, could prevent the develop-
ment of obesity and reduce inflammation in cells and adipose
tissues in DIO mice. Our study suggests that 11b-HSD1 is an
important regulator at the interface of obesity and inflammation,
and maybe be a promising target of obesity-associated diseases.
Materials and Methods
Ethics Statement
All animal and tissue sample experiments were performed in
accordance with the guidelines of the National Institutes of Health
and Nanjing Medical University with procedures(ID:2082101)
approved by the Institutional Animal Care and Use Committee of
the university.
Reagents
BVT.2733, an 11b-HSD1 selective inhibitor was synthesized
according to the patent information by China Pharmaceutical
University. Anti-F4/80 antibody was purchased form Serotec
(Oxford, UK). Phycoerythrin-Cy5 conjugated anti-mouse F4/80
antibody was purchased form eBioscience (San Diego,CA, USA).
Phycoerythrin anti-mouse CD11b and Alexa Fluor488 anti-mouse
CD11c antibodies were purchased from BioLegend (San Die-
go,CA). RU486, corticotisone, LPS and PA were purchased from
(Sigma-Aldrich, St. Louis, MO). M-MLV, dNTP, RNase inhibitor
and other reverse transcription reagents were purchased from
Promega Corp (Madison, WI, USA). Trizol were purchased from
Invitrogen (Carlsbad, CA, USA).
Animals
Male C57BL/6J mice at age of 18 days were purchased from
Slac Laboratories (Shanghai, China). In all experiments, mice
were housed three or four per cage in a room kept at 2361uC with
a 12-h light, 12-h dark cycle and were allowed free access to water
and food. From 3 weeks of age, all mice were fed with a normal
chow diet containing 10% calory from fat (NC mice) (Collabo-
rative Bio-Engineering Corporation, Nanjing, China), or a high fat
diet (HFD) containing 50% calorie from fat (Collaborative Bio-
Engineering Corporation, Nanjing, China) for 24 weeks. During
the last four weeks the HFD-fed mice were dosed (09.00 and
17.00 h) with BVT.2733 (100 mg/kg, orally) (HFD+BVT mice) or
vehicle (HFD mice). Body weight and food intake were determined
weekly. At the time of sacrifice, trunk blood was collected,
centrifuged, and stored at 220uC. Adipose tissues were weighed,
frozen in liquid nitrogen, and stored at 280uC.
Intraperitoneal Glucose Tolerance Test
The mice were fasted overnight and then injected intraperito-
neally with 2 mg/g D-glucose (25% stock solutionin saline). Blood
samples were taken by tail venesection at 0 min (before injection
and within 1 min of disturbing the cage) and at 15-, 30-, 60-, and
120-min intervals after the glucose load. Glucose was measured
with the Accu-Chek Aviva system (Roche, Germany) at 0-, 15-,
30-, 60-, and 120-min post glucose load. Insulin was measured
Figure 4. Effect of HFD and BVT.2733 treatment on the inflammation gene expression in the adipose tissue and the level of
circulating inflammation markers. A–C, The mRNA expression of IL-6, TNF-a and MCP-1 in adipose tissue. D–E, Plasma concentrations of IL-6,
TNF-a and MCP-1. The results are shown as the means 6 SEM. *, P,0.05; **, P, 0.01 compared with NC group; #, P,0.05; ##, P,0.01 compared
with HFD group. n=526 animals per group.
doi:10.1371/journal.pone.0040056.g004
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Corporation, MA, USA) at 0-, 15-, 30-, 60-min post glucose load.
Immunohistochemistry of Macrophages in White
Adipose Tissues
Portions of epididymal adipose tissue were removed and fixed
with 10% formaldehyde and embedded in paraffin. Sections were
stained with hematoxylin and eosin. For the detection of
macrophage infiltration in adipose tissue, immunohistochemistry
was performed with F4/80 antibody, which detected macrophage-
specific protein. The number of F4/80-positive cells was counted
in a blinded fashion under a microscope with a 4006 objective.
More than 50 serial fields were examined in each mouse, and five
mice were analyzed per group.
Isolation of Adipocytes and Stromal-vascular Fractions
Epididymal adipose tissues from mice were rinsed in saline,
minced into fine pieces, and digested with collagenase (Sigma-
Aldrich, St. Louis, MO) with Krebs-Hense-leit-HEPES buffer,
pH 7.4, supplemented with 20 mg/ml of BSA and 2 mmol/l
glucose at 37uC using a shaker for 45 min. Then, the samples were
passed through a mesh and fractionated by brief centrifugation
(1,000 rpm). The pellets or the floating cells were collected as the
stromal-vascular fraction (SVF) or as the adipocyte fraction,
respectively. Cells in each fraction were used for flow cytometry
analysis.
Flow Cytometry Analysis
Cells in the SVF were incubated with Fc Block (BD
Biosciences, San Jose, CA) for 20 min at 4uC prior to staining
with fluorescently labeled primary antibodies or control IgGs for
25 min at 4uC. Then cells were gently washed twice and
resuspended in FACS buffer with propidiumiodide (Sigma-
Aldrich). SVF were analyzed using FACS Calibur and FACS
Aria flow cytometers (BD Biosciences). Unstained, single stains,
and fluorescence minus one controls were used for compensa-
tion and gates settings. The data analysis was performed using
FlowJo (Tree Star, Ashland, OR). Macrophages were identified
Figure 5. Effect of 11b-HSD1 on the inflammation gene expression in PA or LPS-activated J774A.1 macrophages in vitro. A, J774.1
macrophages were treated with palmitic acid (PA) (502200 mmol/L) or LPS (100 ng/ml) for 24 h. B–C, J774.1 macrophages were activated by PA
(200 mmol/L) or LPS (100 ng/ml) and co-treated with 11b-HSD1 inhibitor BVT.2733 (252100 mmol/L) for 24 h. D–G, J774.1 macrophages were
transfected with either sh-RNA for mouse 11b-HSD1 (sh-HSD1) or a negative control (sh-con) by Lentivirus. After 72 h incubation, cells were treated
with PA (200 mmol/L) or LPS (100 ng/ml) for 24 h. Efficiency of 11b-HSD1 knockdown on mRNA level (D) and protein level (E). Effects of knockdown of
11b-HSD1 on MCP-1, IL-6, and TNF-a expression in PA (F) or LPS (G) treated macrophages. H–K, J774.1 macrophages were transfected with the
expression vector for 11b-HSD1 (HSD1) or a corresponding empty vector (emp) using Lentivirus. After 72 h incubation, cells were treated with PA
(100 mmol/L) or LPS (50 ng/ml) and co-treated with 11b-HSD1 inhibitor BVT.2733 for 24 h. Efficiency of 11b-HSD1 overexpression on mRNA level (H)
and protein level (I). Effects of overexpression of 11b-HSD1 on MCP-1, IL-6, and TNF-a expression in PA (J) or LPS (K) treated macrophages. mRNA for
IL-6, MCP-1 and TNF-a were determined by real-time PCR, protein of 11b-HSD1 were determined by Western blot. The results are shown as the means
6 SEM of three individual experiments. *P,0.05; **P,0.01 vs con (B, C, F, G) or sh-con (D) or emp (H) or emp+PA (J) or emp+LPS (K). # P,0.05;
## P,0.01 vs PA (B) or LPS (C) or sh-con+PA (F) or sh-con+LPS (G) or HSD1+PA (J) or HSD1+LPS (K).
doi:10.1371/journal.pone.0040056.g005
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positive/CD11b-positive/CD11c-positive cells, respectively. The
numbers of macrophages were shown according to the
percentage of each fraction per 10000 cells.
Serum Analysis
Serum levels of adiponectin and leptin were determined using
commercially available ELSA kits from Millipore (Millipore
Corporation, MA) and Linco (LINCO Research Inc., St. Charles,
MO) individually. Proinflammatory cytokines interleukin-6 (IL-6),
monocyte chemoattractant protein-1 (MCP-1) and tumour necro-
sis factor a (TNF a) were determined using the mouse
commercially available kit from Bender (Bender MedSystems,
Austria). All assays were performed according to the manufactur-
er’s protocol.
Cell Culture
The mouse reticulum cell sarcoma-derived cell, J774.1, was
obtained from the American Type Culture Collection (ATCC,
Manassas, VA), and maintained in RPMI 1640 supplemented with
10% heat-inactivated FBS(Life Technologies Corporation, USA)in
a humidified 37uC/5% CO2 incubator. Some J774.1 was
maintained in RPMI 1640 supplemented with 10% Charcoal
Dextran Stripped Serum (Life Technologies Corporation, USA) as
indicated. The mouse fibroblast 3T3-L1 preadipocytes was
obtained from ATCC and maintained in DMEM culture medium
supplemented with 10% fetal calf serum and 4 mM glutamine.
Plasmids and Lentiviral Vectors
Full-length mouse cDNA sequence for 11b-HSD1 was cloned
into pLL3.7-BSD lentiviral vector. The RNAi construct for 11b-
HSD1 was generated using one sequence in the coding region of
11b-HSD1: 59 -GTACGGAACTGCATAAGCA-39 (Sigma). Ol-
igonucleotides containing this sequence or random sequence were
subcloned into the lentiviral vector.
Lentivirus Production and Infection of J774A.1
Macrophage and 3T3-L1 Preadipocyte
Recombinant lentiviruses were produced by cotransfecting
293T cells with the lentivirus expression plasmid and packaging
plasmids using Lipofectamine 2000 (Invitrogen) according to
themanufacturer’s instruction. Infectious lentiviruses were harvest-
ed at 48 after transfection and filtered through 0.45 m cellulose
acetate filters. The infection of 3T3-L1 preadipocytes and J774A.1
macrophages was carried out by adding lentivirus into the cell
culture; the controls were infected with scrambled shRNA or
vector. 12 hours after the incubation, the medium was changed.
Infected cells were selected with BSD (3 mg/ml).
Preparation of PA
To avoid bacterial LPS contamination, [36,37] PA were
reconstituted to 10 mmol/L in ethanol, and diluted directly into
warmed culture medium for experiments.
RNA Preparation and Quantitative Real-time PCR
Total RNA was extracted from epididymal adipose tissues
using TRIZOL reagent (Invitrogen) according to the manufac-
turer’s instructions. Two micrograms of total RNA were
reverse-transcribed with 200 U Moloney murine leukemia virus
reverse transcriptase (M-MLV, Promega, Madison, WI, USA),
and in the presence of 0.5 mmol/L deoxynucleotide triphos-
Figure 6. Effect of 11b-HSD1 on the inflammation gene expression in PA or LPS-activated 3T3-L1 preadipocytes in vitro. 3T3-L1
preadipocytes were activated by PA (200 mmol/L) (A) or LPS (200 ng/ml) (D) and co-treated with 11b-HSD1 inhibitor BVT.2733 (502100 mmol/L) for
24 h. 3T3-L1 preadipocytes were transfected with either sh-RNA for mouse 11b-HSD1 (sh-HSD1) or a negative control (sh-con) by Lentivirus. Cells
were treated with PA (200 mmol/L) (B) or LPS (200 ng/ml) (E) for 24 h. 3T3-L1 preadipocytes were transfected with the expression vector for 11b-HSD1
(HSD1) or a corresponding empty vector (emp) using Lentivirus. Cells were treated with PA (200 mmol/L) (C) or LPS (200 ng/ml) (F) for 24 h. mRNA for
IL-6, MCP-1 and TNF-a were determined by real-time PCR. The results are shown as the means 6 SEM of three individual experiments. *P,0.05;
**P,0.01 vs con (A, B, D, E) or or emp+PA (C) or emp+LPS (F). # P,0.05 vs PA (A) or LPS (D) or sh-con+PA (B) or sh-con+LPS (E) or HSD1+PA (C) or
HSD1+LPS (F).
doi:10.1371/journal.pone.0040056.g006
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in a total volume of 25 ml. PCR primers were designed by
Primer5 software. The sequences of the primers used are
available upon request. Each quantitative real-time PCR was
carried out in triplicate, in a 25 ml volume of SYBR Green
Real-time PCR Master Mix (Toyobo, Osaka, Japan). The PCR
program was designed as follows: 60 s at 95uC, followed by 40
cycles of 15 s at 95uC, 15 s at 60uC, 45 s at 72uC, and 5 s at
80uC on the plate reader (Rotor Gene-3000, Corbett Research,
Sydney, Australia). All data were analyzed using the expression
of the gene encoding b-actin as an internal reference.
Expression for each gene is arbitrarily set at 1 to facilitate
comparison between several groups.
Western Blot Analysis
For western blot analysis, cells or tissues were lysed in RIPA
buffer (0.5% NP-40, 0.1% SDS, 150 mM NaCl, 50 mM Tris-Cl
[pH 7.5]). Proteins were separated by SDS-PAGE, transferred to
PVDF membrane (Millipore) and probed with anti-11b-HSD1
(Abcam), and anti-Tubulin (Abcam) antibodies.
Statistics
Comparisons were performed using the Student’s t test for two
groups, or ANOVA for multiple groups. Results are presented as
means 6 SEM. A p value of less than 0.05 was considered
statistically significant.
Supporting Information
Figure S1 Effect of BVT.2733 on the adipokines gene
expression in 3T3-L1 adipocyte. 3T3-L1 preadipocytes were
induced to differentiation adipocyte, d0, d4, d8 cells were
harvested for the mRNA analyses of MCP-1 (A). Preadipocytes
and fully differentiation adipocytes were activated by LPS(0.01–
10 mg/ml) separately for 24 h (B). Fully differentiation adipocytes
were activated by PA(100 mmol/L) or coatreated with BVT.2733
for 24 h (C), mRNA for MCP-1, Vaspin and Resistin were
determined by real-time PCR. The results are shown as the means
6 SEM. *, P,0.05; **, P, 0.01 compared with d0 or con group;
#, P,0.05; ##, P,0.01 compared with PA group.
(TIF)
Figure S2 Effect of 11b-HSD1 on the inflammation
protein levels in medium in vitro. J774.1 macrophages were
Figure 7. Effect of glucocorticoid receptor (GR) on proinflammatory properties of 11b-HSD1 in J774A.1 macrophages. A, J774A.1
macrophages were transfected with the expression vector for 11b-HSD1 (HSD1) or a corresponding empty vector (emp) using Lentivirus. Cells were
treated with PA (100 mmol/L) or co-treated with glucocorticoid antagonist RU486 for 24 h. B, J774A.1 macrophages were activated by LPS(100 ng/ml)
in the absence (con) or presence of increasing amounts of corticosterone (10
210 Mt o1 0
26 M) for 24 h in steroid hormones free media. C, J774A.1
macrophages were activated by LPS (100 ng/ml) in the absence (con) or presence of increasing amounts of 11-dehydro corticosterone (10
210 Mt o
10
25 M) for 24 h in Charcoal Dextran Stripped Serum media. D, J774A.1 macrophages were transfected with the expression vector for 11b-HSD1
(HSD1) or a corresponding empty vector (emp) using Lentivirus. Cells were activated by LPS(100 ng/ml) in the absence (con) or presence of
increasing amounts of 11-dehydro corticosterone (10
211 Mt o1 0
25 M) for 24 h in Charcoal Dextran Stripped Serum media. mRNA for IL-6, MCP-1 and
TNF-a were determined by real-time PCR. The results are shown as the means 6 SEM of three individual experiments. *P,0.05; **P,0.01 vs emp+PA
(A) or con (B–C) or emp (D), # P,0.05 vs HSD1+PA (A).
doi:10.1371/journal.pone.0040056.g007
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inhibitor BVT.2733 (50–100 mmol/L) for 24 h, concentrations of
MCP-1 (A)and IL-6(C)in the media were measured by ELISA.
J774.1 macrophages were transfected with the expression vector
for 11b-HSD1 (HSD1) or a corresponding empty vector (emp)
using Lentivirus. After 72 h incubation, cells were treated with PA
(100 mmol/L) and co-treated with 11b-HSD1 inhibitor BVT.2733
for 24 h; concentrations of MCP-1 (B) and IL-6 (D) in the media
were measured by ELISA. The results are shown as the means 6
SEM. *, P,0.05; **, P, 0.01 compared with con or emp+PA
group; #, P,0.05; ##, P,0.01 compared with PA or HSD1+PA
group.
(TIF)
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